Stock Events

Stock Events

Tscan Therapeutics 

$1
0
-$0.01-0.99% Today

Statistics

Day High
1.05
Day Low
0.98
52W High
-
52W Low
-
Volume
1,193
Avg. Volume
-
Mkt Cap
52.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 18
$0.42
Sep 18
$0.42
Jun 18
$0.42
Mar 18
$0.42
Dec 17
$0.42
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.33
-0.28
-0.23
-0.18
Expected EPS
-0.2025
Actual EPS
N/A

Financials

-4,527.66%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
5.63MRevenue
-255MNet Income

Analyst Ratings

$6.00Average Price Target
The highest estimate is 7.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCRX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for oncology, overlapping with Tscan's focus.
Novartis
NVS
Mkt Cap237.61B
Novartis, with its approved CAR-T cell therapy Kymriah, competes in the oncology treatment space, similar to Tscan's focus.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR-T therapies for cancer, competing in the broader cell therapy market against Tscan.
Precigen
PGEN
Mkt Cap1.46B
Precigen operates in the gene and cell therapy sector focusing on oncology, which includes competing technologies to Tscan's TCR therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR-T projects, competing in the innovative therapy space for cancer.

About

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
ISIN
US89854M1018

Listings

XNAS
US
TCRX
BOATS
BOATS
TCRX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tscan Therapeutics stock price today?▼
The current price of TCRX.BOATS is $1 USD — it has decreased by -0.99% in the past 24 hours. Watch Tscan Therapeutics stock price performance more closely on the chart.
What is Tscan Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tscan Therapeutics stocks are traded under the ticker TCRX.BOATS.
What is Tscan Therapeutics market cap?▼
Today Tscan Therapeutics has the market capitalization of 52.47M
When is the next Tscan Therapeutics earnings date?▼
Tscan Therapeutics is going to release the next earnings report on May 12, 2026.
What were Tscan Therapeutics earnings last quarter?▼
TCRX.BOATS earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.27 USD resulting in a +33.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tscan Therapeutics revenue for the last year?▼
Tscan Therapeutics revenue for the last year amounts to 5.63M USD.
What is Tscan Therapeutics net income for the last year?▼
TCRX.BOATS net income for the last year is -255M USD.
Does Tscan Therapeutics pay dividends?▼
Yes, TCRX.BOATS dividends are paid quarterly. The last dividend per share was 0.42 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Tscan Therapeutics complete a stock split?▼
Tscan Therapeutics has not had any recent stock splits.